How a Most Unlikely Drug Changed the Outcome of Pulmonary Arterial Hypertension

ABSTRACT Epoprostenol is a prostaglandin that was first identified by investigators in 1976 and found to be a potent vasodilator and inhibiter of platelet aggregation, initially in animal studies and subsequently in humans. Based on these properties epoprostenol, which has a short half‐life of sever...

Full description

Saved in:
Bibliographic Details
Main Authors: Ivan M. Robbins, Anna R. Hemnes
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Pulmonary Circulation
Subjects:
Online Access:https://doi.org/10.1002/pul2.70059
Tags: Add Tag
No Tags, Be the first to tag this record!